Cited by 122Nerve injury and regenerationNeuroinflammation and Neurodegeneration MechanismsMesenchymal stem cell research

Down‐regulation of neurocan expression in reactive astrocytes promotes axonal regeneration and facilitates the neurorestorative effects of bone marrow stromal cells in the ischemic rat brain

Open access
Shen, Li Hong, Li, Yi, Gao, Qi, Savant‐Bhonsale, Smita, Chopp, Michael·2008·Glia

Abstract

The glial scar, a primarily astrocytic structure bordering the infarct tissue inhibits axonal regeneration after stroke. Neurocan, an axonal extension inhibitory molecule, is up‐regulated in the scar region after stroke. Bone marrow stromal cells (BMSCs) reduce the thickness of glial scar wall and facilitate axonal remodeling in the ischemic boundary zone. To further clarify the role of BMSCs in axonal regeneration and its underlying mechanism, the current study focused on the effect of BMSCs on neurocan expression in the ischemic brain. Thirty‐one adult male Wistar rats were subjected to 2 h of middle cerebral artery occlusion followed by an injection of 3 × 10 6 rat BMSCs (n = 16) or phosphate‐buffered saline (n = 15) into the tail vein 24 h later. Animals were sacrificed at 8 days after stroke. Immunostaining analysis showed that reactive astrocytes were the primary source of neurocan, and BMSC‐treated animals had significantly lower neurocan and higher growth associated protein 43 expression in the penumbral region compared with control rats, which was confirmed by Western blot analysis of the brain tissue. To further investigate the effects of BMSCs on astrocyte neurocan expression, single reactive astrocytes were collected from the ischemic boundary zone using laser capture microdissection. Neurocan gene expression was significantly down‐regulated in rats receiving BMSC transplantation (n = 4/group). Primary cultured astrocytes showed similar alterations; BMSC coculture during reoxygenation abolished the up‐regulation of neurocan gene in astrocytes undergoing oxygen‐glucose deprivation (n = 3/group). Our data suggest that BMSCs promote axonal regeneration by reducing neurocan expression in peri‐infarct astrocytes. © 2008 Wiley‐Liss, Inc.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/glia.20722

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 51 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Meyer-Puttlitz B Junker E Margolis RU Margolis RK Chondroitin sulfate proteoglycans in the developing central nervous system. II. Immunocytochemical localization of neurocan and phosphacan J Comp Neurol 1996 366 1 44 54 8866845

Cited by

Sorted by citations

Authors
Shen, L. H., Li, Y., Gao, Q., Savant‐Bhonsale, S., & Chopp, M.
Affiliations
Henry Ford Health (US)
Corresponding author
Chopp, Michael
Venue
Glia
Publisher
Wiley
Published
2008-07-10
Volume
56
Issue
16
Pages
1747-1754
ISSN
  • 0894-1491 (ISSN-L)
  • 1098-1136
OpenAlex
W2116308146
Cited by
122
References
51
Citations by year
2026: 1 · 2025: 5 · 2024: 2 · 2023: 11 · 2022: 6 · 2021: 9 · 2020: 4 · 2019: 6 · 2018: 4 · 2017: 5 · 2016: 11 · 2015: 10 · 2014: 11 · 2013: 10 · 2012: 11
FWCI
2.31
Type
journal article
Language
en
Open access
Locations
  • Glia (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Neurological Disorders and Stroke (R01NS045041, P01NS42345, P01NS042345, R01 NS45041)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
Keywords
neurocan, reactive astrocytes, mesenchymal stem cells, axon regeneration, stroke, ischemic brain, glial scar, growth-associated protein 43, cell transplantation, peri-infarct zone, oxygen-glucose deprivation, neurorestoration
MeSH terms
Animals, Astrocytes, Cells, Cultured, Gliosis, Male, Nerve Regeneration, Nerve Tissue Proteins, Chondroitin Sulfate Proteoglycans, Proteoglycans, Down-Regulation, Bone Marrow Transplantation, Stromal Cells, Rats, Wistar, GAP-43 Protein, Recovery of Function, Infarction, Middle Cerebral Artery, Growth Cones, Brain Infarction, Hypoxia-Ischemia, Brain, Rats, Neurocan

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review